Pipeline

Curis   is developing targeted small molecule drug candidates for cancer   indications where there are substantial unmet therapeutic needs.

The Hedgehog   pathway inhibitor program in collaboration with Genentech is the   Company's most advanced program with lead small molecule candidate,   GDC-0449, currently being tested in a pivotal Phase II clinical trial in   advanced basal cell carcinoma as well as in a Phase II clinical trial   in advanced ovarian cancer (as a single agent maintenance therapy). In   addition, there are several additional Phase I and II clinical trials   planned and ongoing under a collaboration between Genentech and the   National Cancer Institute.

Curis' second   candidate under collaboration is Debio 0932 (formerly CUDC-305), an   Hsp90 inhibitor, that Curis licensed to Debiopharm Group in August 2009   and that is currently in Phase I clinical testing.

Curis has focused its internal resources on developing additional small molecule targeted cancer drug candidates. Curis recently completed a Phase I clinical trial of CUDC-101, a first-in-class inhibitor of HDAC, EGFR and Her2. The   Company also initiated in August 2010 a Phase Ib expansion trial of   this molecule in patients with gastric, head and neck, breast and liver   cancers and plan to initiate a Phase I/II clinical trial in head and   neck cancer during the second half of 2010.

In   addition, Curis has several programs that are in various stages of   preclinical drug development.  Because of the early stages of   development of these programs, its ability and that of the   Company's collaborators and licensors to successfully complete   preclinical and clinical studies of these product candidates, and   the timing of completion of such programs, is highly uncertain.